Literature DB >> 26359209

Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma.

Rajneet K Oberoi1, Karen E Parrish1, Terence T Sio1, Rajendar K Mittapalli1, William F Elmquist1, Jann N Sarkaria1.   

Abstract

Glioblastoma (GBM) is a lethal and aggressive brain tumor that is resistant to conventional radiation and cytotoxic chemotherapies. Molecularly targeted agents hold great promise in treating these genetically heterogeneous tumors, yet have produced disappointing results. One reason for the clinical failure of these novel therapies can be the inability of the drugs to achieve effective concentrations in the invasive regions beyond the bulk tumor. In this review, we describe the influence of the blood-brain barrier on the distribution of anticancer drugs to both the tumor core and infiltrative regions of GBM. We further describe potential strategies to overcome these drug delivery limitations. Understanding the key factors that limit drug delivery into brain tumors will guide future development of approaches for enhanced delivery of effective drugs to GBM.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  blood-brain barrier; drug delivery; efflux transporters; glioma

Mesh：

Substances：

Year:  2015        PMID： 26359209      PMCID： PMC4677418          DOI： 10.1093/neuonc/nov164

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


  84 in total

Review 1.  Solid lipid nanoparticles for targeted brain drug delivery.

Authors:  Paolo Blasi; Stefano Giovagnoli; Aurélie Schoubben; Maurizio Ricci; Carlo Rossi
Journal:  Adv Drug Deliv Rev       Date:  2007-05-22       Impact factor: 15.470

2.  Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.

Authors:  Rajneet K Oberoi; Rajendar K Mittapalli; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2013-10-10       Impact factor: 4.030

3.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide.

Authors:  S Nakano; K Matsukado; K L Black
Journal:  Cancer Res       Date:  1996-09-01       Impact factor: 12.701

5.  The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.

Authors:  Sagar Agarwal; Ramola Sane; John R Ohlfest; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2010-10-15       Impact factor: 4.030

6.  Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice.

Authors:  C Chu; C Abbara; M S Noël-Hudson; L Thomas-Bourgneuf; P Gonin; R Farinotti; L Bonhomme-Faivre
Journal:  Biochem Pharmacol       Date:  2009-03-03       Impact factor: 5.858

7.  Comparison of 14C-sucrose delivery to the brain by intravenous, intraventricular, and convection-enhanced intracerebral infusion.

Authors:  D R Groothuis; S Ward; A C Itskovich; C Dobrescu; C V Allen; C Dills; R M Levy
Journal:  J Neurosurg       Date:  1999-02       Impact factor: 5.115

8.  Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.

Authors:  Dale Ding; Charles W Kanaly; Darrell D Bigner; Thomas J Cummings; James E Herndon; Ira Pastan; Raghu Raghavan; John H Sampson
Journal:  J Neurooncol       Date:  2009-11-07       Impact factor: 4.130

9.  Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers.

Authors:  R A Kroll; M A Pagel; L L Muldoon; S Roman-Goldstein; S A Fiamengo; E A Neuwelt
Journal:  Neurosurgery       Date:  1998-10       Impact factor: 4.654

10.  Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.

Authors:  Karol M Pawłowski; Joanna Mucha; Kinga Majchrzak; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-06-17       Impact factor: 2.741
View more
  80 in total

Review 1.  The challenges associated with molecular targeted therapies for glioblastoma.

Authors:  Toni Rose Jue; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2016-02-22       Impact factor: 4.130

Review 2.  The Translational Significance of the Neurovascular Unit.

Authors:  Heather L McConnell; Cymon N Kersch; Randall L Woltjer; Edward A Neuwelt
Journal:  J Biol Chem       Date:  2016-12-05       Impact factor: 5.157

3.  Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients.

Authors:  Nader Sanai; Jing Li; Julie Boerner; Karri Stark; Jianmei Wu; Seongho Kim; Alanna Derogatis; Shwetal Mehta; Harshil D Dhruv; Lance K Heilbrun; Michael E Berens; Patricia M LoRusso
Journal:  Clin Cancer Res       Date:  2018-05-24       Impact factor: 12.531

4.  Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma.

Authors:  Janice K Laramy; Minjee Kim; Shiv K Gupta; Karen E Parrish; Shuangling Zhang; Katrina K Bakken; Brett L Carlson; Ann C Mladek; Daniel J Ma; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2017-08-28       Impact factor: 4.030

5.  Self-assembled 20-nm (64)Cu-micelles enhance accumulation in rat glioblastoma.

Authors:  Jai Woong Seo; JooChuan Ang; Lisa M Mahakian; Sarah Tam; Brett Fite; Elizabeth S Ingham; Janine Beyer; John Forsayeth; Krystof S Bankiewicz; Ting Xu; Katherine W Ferrara
Journal:  J Control Release       Date:  2015-10-05       Impact factor: 9.776

Review 6.  CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.

Authors:  Stephen J Bagley; Arati S Desai; Gerald P Linette; Carl H June; Donald M O'Rourke
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

Review 7.  From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence.

Authors:  A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2018-01-15       Impact factor: 3.405

Review 8.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

9.  Local DNA Repair Inhibition for Sustained Radiosensitization of High-Grade Gliomas.

Authors:  Amanda R King; Christopher D Corso; Evan M Chen; Eric Song; Paul Bongiorni; Zhe Chen; Ranjini K Sundaram; Ranjit S Bindra; W Mark Saltzman
Journal:  Mol Cancer Ther       Date:  2017-05-31       Impact factor: 6.261

10.  Targeted Brain Tumor Radiotherapy Using an Auger Emitter.

Authors:  Giacomo Pirovano; Stephen A Jannetti; Lukas M Carter; Ahmad Sadique; Susanne Kossatz; Navjot Guru; Paula Demétrio De Souza França; Masatomo Maeda; Brian M Zeglis; Jason S Lewis; John L Humm; Thomas Reiner
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.